Sweden’s Vitrolife to buy Igenomix in EUR 1.25 billion deal

Swedish medical technology group Vitrolife said on Thursday it would buy reproductive genetic testing services provider Igenomix S.L. in a deal worth 1.25 billion euros ($1.48 billion) on a cash and debt free basis.

Sweden’s Vitrolife to buy Igenomix in EUR 1.25 billion deal
STOCKHOLM (Reuters) – Swedish medical technology group Vitrolife said on Thursday it would buy reproductive genetic testing services provider Igenomix S.L. in a deal worth 1.25 billion euros ($1.48 billion) on a cash and debt free basis.

Tags : business

Sweden’s Vitrolife to buy Igenomix in EUR 1.25 billion deal

Sweden’s Vitrolife to buy Igenomix in EUR 1.25 billion deal

People born by donor eggs or sperm will be able to find out biological origins

I tried to get pregnant for so long – but when it happened I only felt guilt

Ten years of egg freezing – is it time for re-evaluation?

British women turn to IVF clinics in Greece and Turkey to avoid higher costs

Online retailers mislead on ‘egg timer’ fertility test

How common is natural conception in women who have had a livebirth via assisted reproductive technology? Systematic review and meta-analysis

Heparin for women with recurrent miscarriage and inherited thrombophilia (ALIFE2): an international open-label, randomised controlled trial

Effect of dehydroepiandrosterone administration before in vitro fertilization on the live birth rate in poor ovarian responders according to the Bologna criteria: A randomised controlled trial

What is the optimal GnRH antagonist protocol for ovarian stimulation during ART treatment? A systematic review and network meta-analysis

Time-to-conception and clinical pregnancy rate with a myo-inositol, probiotics and micronutrient supplement: secondary outcomes of the NiPPeR Randomized Trial